{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:10:55Z","timestamp":1761894655827,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2008]]},"DOI":"10.1080\/14653240701732771","type":"journal-article","created":{"date-parts":[[2008,1,17]],"date-time":"2008-01-17T07:06:27Z","timestamp":1200553587000},"page":"45-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prevention of graft vs. host disease with alemtuzumab \u2018in the bag\u2019 decreases early toxicity of stem cell transplantation and in multiple myeloma is associated with improved long-term outcome"],"prefix":"10.1016","volume":"10","author":[{"given":"N.","family":"Novitzky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"du Toit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1080\/14653240701732771_bib0005","first-page":"934","article-title":"Melphalan-prednisone versus alternating combination VAD\/MP or VND\/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study","volume":"87","author":"Cavo","year":"2002","journal-title":"Haematologica"},{"key":"10.1080\/14653240701732771_bib0010","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/1097-0142(19821101)50:9<1669::AID-CNCR2820500902>3.0.CO;2-N","article-title":"Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma: Cancer and Leukemia Group B experience","volume":"50","author":"Cornwell","year":"1982","journal-title":"Cancer"},{"key":"10.1080\/14653240701732771_bib0015","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0025-7125(16)31127-0","article-title":"Multiple myeloma","volume":"68","author":"Oken","year":"1984","journal-title":"Med Clin North Am"},{"key":"10.1080\/14653240701732771_bib0020","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1200\/JCO.1996.14.5.1447","article-title":"High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma","volume":"14","author":"Bensinger","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1080\/14653240701732771_bib0025","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","article-title":"Total therapy with tandem transplants for newly diagnosed multiple myeloma","volume":"93","author":"Barlogie","year":"1999","journal-title":"Blood"},{"issue":"Number 3","key":"10.1080\/14653240701732771_bib0030","first-page":"199","article-title":"Autologous stem cell transplantation in multiple myeloma: an update of the EBMT registry","volume":"Volume 67","author":"Bjorkstrand","year":"2001","journal-title":"European Journal of Haematology"},{"key":"10.1080\/14653240701732771_bib0035","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bmt.1702622","article-title":"High-dose therapy autotransplantation\/intensification vs. continued standard chemotherapy in multiple myeloma in first remission: results of a non-randomized study from a single institution","volume":"26","author":"Blade","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1080\/14653240701732771_bib0040","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"New Engl J Med"},{"key":"10.1080\/14653240701732771_bib0045","first-page":"7","article-title":"Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study, Nordic Myeloma Study Group","volume":"95","author":"Lenhoff","year":"2000","journal-title":"Blood"},{"key":"10.1080\/14653240701732771_bib0050","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1182\/blood.V85.6.1596.bloodjournal8561596","article-title":"High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting","volume":"85","author":"Corradini","year":"1995","journal-title":"Blood"},{"key":"10.1080\/14653240701732771_bib0055","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1200\/JCO.2001.19.17.3771","article-title":"Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial","volume":"19","author":"Stewart","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1080\/14653240701732771_bib0060","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","article-title":"Graft-versus-myeloma effect: proof of principle","volume":"87","author":"Tricot","year":"1996","journal-title":"Blood"},{"key":"10.1080\/14653240701732771_bib0065","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1182\/blood.V88.12.4711.bloodjournal88124711","article-title":"Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation","volume":"88","author":"Bjorkstrand","year":"1996","journal-title":"Blood"},{"key":"10.1080\/14653240701732771_bib0070","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1182\/blood.V90.10.4206","article-title":"Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation","volume":"90","author":"Lokhorst","year":"1997","journal-title":"Blood"},{"key":"10.1080\/14653240701732771_bib0075","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1200\/JCO.2000.18.16.3031","article-title":"Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome","volume":"18","author":"Lokhorst","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1080\/14653240701732771_bib0080","first-page":"527","article-title":"Syngeneic marrow transplantation in patients with multiple myeloma","volume":"18","author":"Bensinger","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1080\/14653240701732771_bib0085","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/14653240310004520","article-title":"Campath-1 Abs \u2018in the bag\u2019 for hematological malignancies: The Cape Town experience","volume":"6","author":"Novitzky","year":"2004","journal-title":"Cytotherapy"},{"key":"10.1080\/14653240701732771_bib0090","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/sj.bmt.1702477","article-title":"CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells","volume":"26","author":"Hale","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1080\/14653240701732771_bib0095","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/sj.bmt.1705119","article-title":"Myeloablative conditioning is well tolerated by older patients receiving T-cell depleted grafts","volume":"36","author":"Novitzky","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1080\/14653240701732771_bib0100","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1399-0039.1990.tb01767.x","article-title":"The CAMPATH-1 antigen (Cdw 52)","volume":"35","author":"Hale","year":"1990","journal-title":"Tissue Antig"},{"key":"10.1080\/14653240701732771_bib0105","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1080\/14653240701732771_bib0110","first-page":"871","article-title":"A modified right atrial catheter for access to the venous system in marrow transplant recipients","volume":"148","author":"Hickman","year":"1979","journal-title":"Surg Gynecol Obstet"},{"key":"10.1080\/14653240701732771_bib0115","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/146532401753173990","article-title":"Infectious complications following T-cell depleted hematopoietic stem-cell transplantation","volume":"3","author":"Novitzky","year":"2001","journal-title":"Cytotherapy"},{"key":"10.1080\/14653240701732771_bib0120","doi-asserted-by":"crossref","first-page":"423","DOI":"10.7326\/0003-4819-76-3-112-6-423","article-title":"Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial","volume":"112","author":"Bern","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1080\/14653240701732771_bib0125","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/scd.1.1996.5.213","article-title":"The ISHAGE guidelines for CD34+ cell determination by flow cytometry","volume":"5","author":"Sutherland","year":"1996","journal-title":"J Hematother"},{"key":"10.1080\/14653240701732771_bib0130","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft vs host disease in human recipients of marrow from HLA matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"10.1080\/14653240701732771_bib0135","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies","volume":"20","author":"Orlowski","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1080\/14653240701732771_bib0140","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients","volume":"98","author":"Barlogie","year":"2001","journal-title":"Blood"},{"key":"10.1080\/14653240701732771_bib0145","first-page":"775a","article-title":"A phase I trial of oral CC-5013, an immunomodulatory thalidomide derivative, in patients with relapsed and refractory multiple myeloma","volume":"98","author":"Richardson","year":"2001","journal-title":"Blood"},{"key":"10.1080\/14653240701732771_bib0150","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1182\/blood.V88.12.4711.bloodjournal88124711","article-title":"Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation","volume":"88","author":"Bjorkstrand","year":"1996","journal-title":"Blood"},{"key":"10.1080\/14653240701732771_bib0155","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1200\/JCO.2003.04.033","article-title":"For the Dutch-Belgian Hemato-Oncology Cooperative Group. Partially T-cell depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM","volume":"21","author":"Lokhorst","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1080\/14653240701732771_bib0160","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/bbmt.2003.50009","article-title":"Reduced-intensity transplantation with in vivo T cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity","volume":"9","author":"Peggs","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1080\/14653240701732771_bib0165","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2004-06-2387","article-title":"Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT","volume":"105","author":"Crawley","year":"2005","journal-title":"Blood"},{"key":"10.1080\/14653240701732771_bib0170","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood-2002-09-2687","article-title":"Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications","volume":"102","author":"Morris","year":"2003","journal-title":"Blood"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324908701567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324908701567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T22:11:25Z","timestamp":1761430285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324908701567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008]]}},"alternative-id":["S1465324908701567"],"URL":"https:\/\/doi.org\/10.1080\/14653240701732771","relation":{},"ISSN":["1465-3249"],"issn-type":[{"type":"print","value":"1465-3249"}],"subject":[],"published":{"date-parts":[[2008]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention of graft vs. host disease with alemtuzumab \u2018in the bag\u2019 decreases early toxicity of stem cell transplantation and in multiple myeloma is associated with improved long-term outcome","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1080\/14653240701732771","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}